RecruitingPhase 2NCT05286788
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Studying Adamantinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nationwide Children's Hospital
- Principal Investigator
- Holly Lindsay, MDChildren's Hospital Colorado
- Intervention
- Binimetinib Oral Tablet [Mektovi](drug)
- Enrollment
- 38 enrolled
- Eligibility
- 1-39 years · All sexes
- Timeline
- 2023 – 2027
Study locations (10)
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Sydney Children's Hospital, Randwick, New South Wales, Australia
- Queensland Children's Hospital, South Brisbane, Queensland, Australia
- Perth Children's Hospital, Perth, Western Australia, Australia
- British Columbia Children's Hospital, Vancouver, British Columbia, Canada
- CHU Sainte-Justine, Montreal, Quebec, Canada
Collaborators
Children's Hospital Colorado
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05286788 on ClinicalTrials.govOther trials for Adamantinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05919264FOG-001 in Locally Advanced or Metastatic Solid TumorsParabilis Medicines, Inc.
- RECRUITINGPHASE2NCT05233397ACTEMRA® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaNationwide Children's Hospital
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT03970226Tocilizumab in Children With ACPUniversity of Colorado, Denver